SCHEMBL1682795

SCHEMBL1682795

O=C(Nc1cccc(-c2csc3cnc(Nc4ccc(N5CCOCC5)nc4)nc23)c1)c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 6/20 0.53
▸ PIK3CD O00329 1/20 0.49
▸ PIK3CA P42336 1/20 0.49
▸ MAPT P10636 1/20 0.48
▸ STAT3 P40763 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ BRAF P15056 9/20 0.47
▸ RAF1 P04049 8/20 0.46
▸ JAK2 O60674 1/20 0.45
▸ BRD4 O60885 1/20 0.45
▸ BTK Q06187 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1682874 0.93 PIK3CD (0.56) PTK2PIK3CDPIK3CABRAFRAF1
SCHEMBL13557788 0.84 PTK2 (0.58) PTK2JAK2BRD4BTK
SCHEMBL1682878 0.83 PTK2 (0.65) PTK2JAK2BRD4
SCHEMBL1682819 0.82 PTK2 (0.57) PTK2JAK2BRD4
SCHEMBL1682837 0.81 PTK2 (0.60) PTK2JAK2BRD4
SCHEMBL1682871 0.81 PTK2 (0.62) PTK2BRAFJAK2BRD4
SCHEMBL1682873 0.80 PTK2 (0.61) PTK2JAK2BRD4
SCHEMBL1682798 0.79 PTK2 (0.56) PTK2JAK2BRD4
SCHEMBL1682881 0.78 PTK2 (0.57) PTK2BRAFJAK2BRD4
SCHEMBL1682793 0.78 PTK2 (0.83) PTK2JAK2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586580-B2 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-11-19 — — US claimed
US-20120277424-A1 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-01 — — US claimed
EP-2491043-A2 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KIST Korea Institute of Science and Technology (KR) 2012-08-29 — — EP claimed
WO-2011049332-A2 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2011-04-28 — — WO claimed
US-8586580-B2 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-11-19 — — US disclosed
US-8586580-B2 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-11-19 — — US disclosed
US-20120277424-A1 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-01 — — US disclosed
US-20120277424-A1 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-01 — — US disclosed
US-20120277424-A1 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-01 — — US disclosed
EP-2491043-A2 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KIST Korea Institute of Science and Technology (KR) 2012-08-29 — — EP disclosed
WO-2011049332-A2 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2011-04-28 — — WO disclosed
WO-2011049332-A2 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2011-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277424-A1 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS CDK2, TK1, DTYMK PTK2 292/4885PIK3CD 58/4885PIK3CA 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback